Ozi ndị ọzọ ― Igbo

A maara na laser Q‑switched Nd:YAG na‑agwọ nevus nke Ota na ọnọdụ ndị yiri ya nke ọma. Anyị mere ọmụmụ iji nyochaa otu laser high‑fluence 1064 nm Q‑switched Nd:YAG si arụ ọrụ n’ime ntụpọ Mongolian n'ebe ndị a na‑adịghị ahụkebe, na‑emeghị ka akpụkpọ ahụ gbazee. Anyị nyochara 61 ndị ọrịa nwere ntụpọ ndị a, na‑enyocha ngụkọta nke ọnya 70. A na‑ejiri laser gwọọ ọkara n’ime ọnya, ebe a na‑ahapụ ndị ọzọ n'enweghị ọgwụgwọ. Anyị tụrụ nsonaazụ site n’iji nha na ngwaọrụ akpọrọ Mexameter® tụọ ọkwa melanin. A na‑agbaso ndị ọrịa maka nkezi oge nlekọta nke ọnwa 14 n'ime otu ọgwụgwọ, na ọnwa 18 n'oge nlekọta ọzọ. Na njedebe nke ọmụmụ, anyị hụrụ ọdịiche dị ịrịba ama n’ọkwa melanin n’etiti ndị a na‑agwọ ọrịa na ndị a na‑agaghị agwọ, ebe ndị a na‑agwọ laser gosipụtara nsonaazụ ka mma. Laser high‑fluence Q‑switched Nd:YAG, na‑emeghị ka akpụkpọ ahụ na‑enwu gbaa, gosipụtara na ọ dị mma yana nchekwa maka ịgwọ ntụpọ Mongolian ndị a na‑adịghị ahụkebe.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.

Anyị nyochara uru na nchekwa nke iji ọgwụgwọ laser akọwapụtara maka ABNOM, wee nyochaa ihe ndị nwere ike imetụta otu ọ si arụ ọrụ. Anyị lelee ndị ọrịa 110 nwere ABNOM wee tinye ha n'etiti ọgwụgwọ laser abụọ ruo itoolu. Anyị chọpụtara na ọgwụgwọ ahụ na-arụ ọrụ nke ọma mgbe a na-eme ya, mana ọ bụghị nke ọma n’ụlọ ndị ọrịa meworo agadi. Ọ na-arụkwa ọrụ nke ọma n’ụlọ ndị nwere akpụkpọ anụ ọkụ (ụdị III) na mpaghara ndị dị ntakịrị emetụta (ihe na-erughị 10 cm²). Inwe melasma yana ABNOM mere ka ọgwụgwọ ahụ ghara ịdị irè. Agba ma ọ bụ ọnụọgụgụ mpaghara emetụtara anaghị egosipụta ihe ọ bụla pụrụ iche. Ihe dị ka 10 % nke ndị ọrịa nwetara ntụpọ gbara ọchịchịrị ka a gwọchara ha. Ọgwụgwọ ọtụtụ oge mbụ nyere nsonaazụ dị mma. Ndị ọrịa meworo agadi nwere akpụkpọ ahụ gbara ọchịchịrị na ntụpọ gbara ọchịchịrị na-enwekarị ntụpọ ojii ka a gwọchara ya. Maka ndị ọrịa nwere ABNOM na melasma, ọ ka mma iji laser ike dị ala iji zere ime ka melasma ka njọ.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.